Artisan on Upside Potential of Madrigal Pharmaceuticals

 Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Global markets saw an incredible but volatile second quarter, shifting from deep declines to strong gains. In the quarter, its Investor Class fund ARTSX returned 7.30%, Advisor Class fund APDSX posted a return of 7.33%, and Institutional Class fund APHSX returned 7.36%, compared to a return of 11.97% for the Russell 2000 Growth Index. In addition, you can check the fund’s top 5 holdings to find out its best picks for 2025.

In its second-quarter 2025 investor letter, Artisan Small Cap Fund highlighted stocks such as Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL). Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a biopharmaceutical company. The one-month return of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) was 40.97%, and its shares gained 62.11% of their value over the last 52 weeks. On August 22, 2025, Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) stock closed at $414.68 per share, with a market capitalization of $9.243 billion.

Artisan Small Cap Fund stated the following regarding Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) in its second quarter 2025 investor letter:

"Notable buys in the quarter included BWX Technologies, Wingstop, and Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL). Madrigal Pharmaceuticals is a commercial-stage biotechnology company focused on treating metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need. Madrigal’s lead drug, RezdiffraTM, is the first and only FDA-approved medication to target liver fibrosis, demonstrating high efficacy with minimal side effects. Given the significant failure rates of previous treatments for this condition, we are confident in the company's ability to maintain a competitive edge and further differentiate itself in the market. Additionally, there is potential to expand its application to more advanced stages of liver fibrosis."

https://finance.yahoo.com/news/believe-upside-potential-madrigal-pharmaceuticals-130157124.html